Prss14의 세포내 절편 생성과 그 기능에 대한 연구 by 조영경
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 








Prss14의 세포내 절편 생성과  
그 기능에 대한 연구 
 
 
Studies on the mechanism of regulated 
intramembrane proteolysis of Prss14 and Its 



















Studies on the mechanism of regulated 
intramembrane proteolysis of Prss14 and its 
role in cancer metastasis 
 
Youngkyung Cho 
School of Biological Sciences 
The Graduate School 
Seoul National University 
 
Prss14 (Protease serine 14) is a type II transmembrane serine 
protease widely expressed in epithelial tissues. It has been reported 
that Prss14 is overexpressed in many cancers and plays critical roles 
in cancer initiation, progression, and metastasis. Prss14 undergoes 
ectodomain shedding in response to various stimulus including serum, 
TGF-β, and PMA. The fate of the membrane anchored N-terminal 
fragment (NTF) resulted from ectodomain shedding remains 
unknown. Here I show that the membrane-bound remnant, is 
subjected to regulated intramembrane proteolysis (RIP) and 
translocates to the nucleus. After PMA-induced ectodomain 
shedding of Prss14 mediated by tumor necrosis factor- converting 
enzyme (TACE), the signal peptide peptidase-like 2b (SPPL2b) 
cleaves the N-terminal fragment. The generated soluble Prss14 
intracellular domain (PICD) is liberated from the membrane and move 
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to the nucleus, where it regulates transcription. Strategic RNA-seq 
analyses revealed the PICD target genes including transcription 
factors, cytokines, migration and invasion-associated genes, and 
ubiquitin proteasome pathway-associated genes. The network 
analysis showed that these genes are well associated in three sub-
networks centered on Fos, Tnf, and Ubc. PICD target genes are 
known for the functions of cell migration, invasion, epithelial-
mesenchymal transition (EMT), and modulation of cancer 
microenvironment. The ability of cell invasion and migration is 
abolished when SPPL2b was knocked down and it is recovered by 
transfection of exogenous PICD (N55). Furthermore, the cells 
expressing Flag-tagged N55 show EMT-like scattered cellular 
morphology. In addition, the epithelial marker E-cadherin is 
decreased and mesenchymal marker Vimentin is increased in Flag-
N55-expressed cells, demonstrating that PICD itself can induce 
EMT. The survival of estrogen receptor (ER)-negative breast 
cancer patients with high PRSS14 expression is poorer in the patients 
with high level of PRSS14 and SPPL2B. Also, ER-negative patients 
expressing high level of PRSS14 and PICD target genes are able to 
use for the good prognosis markers for ER-negative breast cancer. 
Therefore, these results suggest that a novel mechanism of PICD to 
promote cancer metastasis by increasing cell invasion and EMT and 
modulating cancer microenvironment through transcriptional 
regulation. I propose that the dual function of Prss14 plays in cancer 
metastasis, by affecting target gene expression with intracellular 
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Prss14 in cancer progression 
Proteases are involved in many processes of cancer progression. 
They degrade the extracellular matrix (ECM) molecules and allow 
the cancer cells to migrate basement membrane and invade into the 
surrounding tissues and vasculature. In many cancers, the proteases 
including cathepsins, matrix metalloproteases (MMPs), and serine 
proteases are upregulated (Affara et al., 2009; Deryugina and 
Quigley, 2006; Friedl and Wolf, 2003; Mohamed and Sloane, 2006; 
Netzel-Arnett et al., 2003). Recently, there have been many reports 
that proteases not only provide the way to migrate for cancer cells, 
but also activate pro-tumorigenic signaling pathway. 
Among these proteases, the type II transmembrane serine 
protease (TTSPs) localized at the at cell surface have been known 
to play critical roles to cleave cytokines, growth factors, and 
receptors, such as VEGF, HGF, and uPAR and activate signaling 
pathways (Affara et al., 2009; Sevenich and Joyce, 2014). Cell 
surface localization allows TTSPs efficiently mediate signal 
transduction between the cancer cells and their surrounding 
environment. 
Prss14 (Protease serine 14) is one of the most studied members 
of TTSPs. It is also known as epithin (Kim et al., 1999), matriptase 
(Lin et al., 1999b), ST14 (Zhang et al., 1998), and membrane type 
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serine protease 1 (MT-SP1) (Takeuchi et al., 1999). Prss14 has a 
multidomain structure, containing a short cytoplasmic tail, two Cls/Clr, 
urchin embryonic growth factor, bone morphogenetic protein (CUB) 
domains, four low-density lipoprotein receptor class A repeats, and 
serine protease domain (Fig. 1). The cytoplasmic domain has been 
reported to interact with filamin and translocate Prss14 to cell 
surface (Kim et al., 2005). The CUB domains and LDLRA repeats 
participate in zymogen activation (Inouye et al., 2013). In addition, 
second CUB domain interacts with HAI-1 and facilitates inhibitory 
interaction between Prss14 and HAI-1 (Inouye et al., 2010). LDLRA 
domains provide the specific binding sites for Tie2 and allow Prss14 
to cleave Tie2 (Kim et al., 2011). Prss14 cleaves and activates 
diverse substrates, such as hepatocyte growth factor (HGF) (Lee et 
al., 2000), urokinase type plasminogen activator (uPA) (Lee et al., 
2000), protease activated receptor (PAR) 2 (Takeuchi et al., 2000), 
epidermal growth factor receptor (EGFR) (Chen et al., 2008), Tie2 
(Kim et al., 2011), MMP3 (Jin et al., 2006), prostasin (Netzel-Arnett 
et al., 2006), and extracellular matrix proteins (Tripathi et al., 2011). 
Its proteolytic activity is regulated by a Kunitz-type serine protease 
inhibitors, hepatocyte growth factor activator inhibitor 1 and 2 (HAI-
1 and HAI-2) (Lin et al., 2008; Szabo et al., 2008). HAIs are co-
expressed with Prss14 in epithelium and tightly regulate proteolytic 













Figure 1. Domain structure of Prss14  
Prss14 has a multidomain structure, containing a short cytoplasmic 
tail, two Cls/Clr, urchin embryonic growth factor, bone 
morphogenetic protein (CUB) domains, four low-density lipoprotein 







Prss14 is expressed almost epithelial tissues. Its upregulation 
has been shown in variety of human epithelial cancers, such as breast, 
prostate, ovary, cervix, colon, and esophagus, indicating the critical 
roles in cancer initiation and progression (List, 2009; Uhland, 2006). 
Furthermore, increased Prss14 expression was tightly linked to 
tumor grade and poor survival in cancer patients (Chang et al., 2013; 
Ha et al., 2014; Kang et al., 2003; Kim et al., 2016; Lee et al., 2005; 
Oberst et al., 2001; Oberst et al., 2002; Saleem et al., 2006; Tsai et 
al., 2014). Transgenic mice expressing Prss14 in the epidermis by 
K5-promoter showed spontaneous cell carcinogenesis, suggesting 
the direct evidences that Prss14 was involved in cancer initiation and 
development (List et al., 2005). Another animal studies showed that 
mice injected with cells increased Prss14 presented remarkable 
increased angiogenesis, invasive growth, and metastasis (Ihara et al., 
2002; Jin et al., 2006). Conversely, tumor formation and metastasis 
were severely impaired in injected by cells with reduced Prss14 
expression or activity (Cheng et al., 2013; Kim et al., 2011; Ko et al., 
2015; List et al., 2005; Steinmetzer et al., 2006; Tsai et al., 2014).  
In our previous studies, the soluble secreted form of Prss14 
could induce angiogenesis by increasing the migration, invasion of 
endothelial cells (Kim et al., 2010). Prss14 cleaved and activated 
Tie2 on endothelial cells to enhance the TEM of cancer cells (Kim et 
al., 2011). Prss14-dependent TEM was also observed in activated 
macrophages (Lee et al., 2011). In addition to these extracellular 
functions, Prss14 expression itself induced mesenchymal 
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characteristics in MDCK epithelial cell line accompanied by genetic 
reprograming within these cells (Lee et al., 2010). However, how 




Prss14 undergoes multiple processing steps 
Prss14 undergoes series of proteolytic processing steps prior to 
becoming a functional protease by autocatalysis at Arg614 (Uhland, 
2006). Prss14 synthesized as a single-chain zymogen is cleaved at 
Gly149 to produce two fragments, N-terminal fragment (NTF) and 
Prss14-S, which are non-covalently associated on the membrane 
(Cho et al., 2001). The protein is shed from the membrane by 
cleavage at Arg186, Lys189, or Lys204. This shedding is induced by 
various stimuli such as the serum (Benaud et al., 2001), phorbol 12-
myristate 13-acetate (PMA) (Kim et al., 2005), transforming growth 
factor- (TGF-) (Lee et al., 2014), hypoxia (Kim et al., 2010), and 
acidic conditions (Tseng et al., 2017). The ectodomain shedding is 
mediated by TACE/ADAM17 (Cho et al., 2017; Lee et al., 2014) 
and/or serine protease, possibly Pss14 itself (Tseng et al., 2017). 
However, the fate of the remaining N-terminal fragment (NTF) of 











Figure 2. Multiple processing steps of Prss14 
Prss14 is synthesized as a single-chain zymogen and cleaved at 
Gly149 to produce two fragments, N-terminal fragment (NTF) and 
Prss14-S, which are non-covalently associated on the membrane in 
ER. After this N-terminal processing, Prss14 is shed from the 
membrane by cleavage at Arg186, Lys189, or Lys204 upon various 







Regulated intramembrane proteolysis 
Some membrane proteins undergoing ectodomain shedding is 
further processed by regulated intramembrane proteolysis (RIP). 
RIP has received considerable attention as the fundamental process 
producing messengers for signal transduction and affecting the 
diverse cellular processes, such as cell differentiation, proliferation, 
apoptosis, and neurogenesis (Brown et al., 2000; Lal and Caplan, 
2011). RIP is generally preceded by initial ectodomain shedding and 
cleaves the membrane-bound remnant. After this cleavage, the 
generated intracellular domain (ICD) is liberated from membrane 
(Fig.3). This released ICD functions as a signaling molecule in 
cytosol or a transcriptional regulator after translocation to the 
nucleus (Brown et al., 2000).  
The intramembrane protease to carry out RIP includes three 
distinct protease families, the site-2 protease-type 
metalloproteases, the rhomboid serine proteases, and Presenilins and 
signal peptide peptidase (SPP)-type aspartic proteases (Weihofen 
and Martoglio, 2003). In the aspartic protease family, presenilins and 
SPP-like proteases (SPPLs) strictly prefer to cleave the type I and 
type II transmembrane protein, respectively (Fluhrer et al., 2009). 
Each SPPL members is localized in different subcellular 
compartments: SPPL2a in the lysosome and late endosomes, SPPL2b 
in the plasma membrane, SPPL2c in the ER, and SPPL3 in the Golgi. 
In line with their distinct localization, it is thought that each member 









Figure 3. Regulated intramembrane proteolysis 
After ectodomain shedding, some transmembrane proteins are 
subjected to intramembrane cleavage to generate intracellular 
domain (ICD). This ICD liberated from membrane is degraded or 
functions as a signaling molecule in cytosol, or translocate to the 
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(Friedmann et al., 2006; Krawitz et al., 2005; Voss et al., 2013) 
    The improper control of RIP leads to various diseases (Lal and 
Caplan, 2011; Lichtenthaler et al., 2011). Too much RIP of amyloid 
precursor protein (APP) by presenilin can lead to the Alzheimer’s 
disease (Hardy and Selkoe, 2002). For epithelial cell adhesion 
molecule (EpCAM), dysregulated RIP promotes the cancer initiation 
and progression upregulating genes involved in cell proliferation, 










Metastasis is a multistep process including angiogenesis, 
epithelial mesenchymal transition (EMT), migration, invasion, 
transendothelial migration (TEM), and colonization in secondary 
organs (Chambers et al., 2002; Gupta and Massague, 2006). 
Especially, EMT involves the massive changes in gene expression 
profiles and is the critical process to confer highly increased motility 
and invasiveness. EMT is driven by the EMT-inducing transcription 
factors, such as well studied SNAI1, SNAI2, TWIST1, ZEB1, and 
ZEB2 (Thiery, 2002; Yang and Weinberg, 2008). More transcription 
factors including SOX4 and RUNX besides these transcription factors 
were also demonstrated to induce the EMT process (Lourenco and 
Coffer, 2017; Voon and Thiery, 2017). In addition, editing of cancer 
by immune cells is important during cancer progression and 
metastasis. Cancer cells modulate the immune system to create 
favorable tumor microenvironment for cancer. Cytokines produced 
by the cancer cells are the key mediators to escape the immune 
response and to further facilitate the metastatic steps (Kitamura et 
al., 2015; Schreiber et al., 2011). 
Prss14 (Protease serine 14), also known as epithin (Kim et al., 
1999), matriptase (Lin et al., 1999b), ST14 (Zhang et al., 1998), and 
membrane type serine protease 1 (MT-SP1) (Takeuchi et al., 1999), 
is a type II transmembrane serine protease that plays multiple critical 
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roles during cancer metastasis processes. Many studies showed that 
Prss14 was upregulated in variety of human epithelial cancers, such 
as breast, prostate, ovary, cervix, colon, and esophagus (List, 2009; 
Uhland, 2006). Its increased expression was tightly linked to higher 
tumor grade and poor survival in patients (Chang et al., 2013; Friis 
et al., 2014; Kang et al., 2003; Kim et al., 2016; Lee et al., 2005; 
Oberst et al., 2001; Oberst et al., 2002; Saleem et al., 2006; Tsai et 
al., 2014). In previous studies, it was demonstrated that Prss14 had 
crucial functions in every steps of metastasis. The soluble secreted 
form of Prss14 could promote angiogenesis by enhancing migration, 
invasion, and tube formation of endothelial cells (Kim et al., 2010). 
In addition, overexpression of Prss14 induced EMT, thereby 
increased cell migration and invasion and TGF-β-induced EMT was 
observed in Prss14-dependent manner (Lee et al., 2010). These 
results imply its essential role in EMT but the mechanism underlying 
Prss14-mideated EMT remains still unknown. Prss14 also enhanced 
TEM of cancer cells by cleaving and activating Tie2 (Kim et al., 
2011). Furthermore, metastasis was severely impaired in mice 
injected by breast cancer cells with reduced Prss14 level (Kim et al., 
2011). In another studies, downregulation of Prss14 and inhibition of 
its activity significantly reduced metastasis in xenograft mice model 
(Cheng et al., 2013; Ko et al., 2015; Steinmetzer et al., 2006; Tsai et 
al., 2014). Conversely, when cancer cells with increased Prss14 or 
active form of Prss14 were grafted to immunodeficient mice, 
remarkable increased angiogenesis, invasive growth, and metastasis 
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were observed (Ihara et al., 2002; Jin et al., 2006). The transgenic 
mice expressing Prss14 in the epidermis showed the increased 
invasive tumor growth and metastasis in presence of carcinogen (List 
et al., 2005). This mice model also displayed spontaneous squamous 
cell carcinogenesis, indicating that Prss14 was also required for 
tumor initiation and tumor growth. Another mice model that 
genetically reduced Prss14 expression showed severely impaired 
tumor formation and growth (Zoratti et al., 2015). 
Prss14 undergoes series of proteolytic processing to be a 
functional protease (List et al., 2006). During biogenesis, Prss14 
synthesized as a single chain zymogen is cleaved at Gly149 and 
becomes the membrane-localized form in which cleaved 
extracellular region is non-covalently associated with N-terminal 
fragment (NTF) (Cho et al., 2001). To possess proteolytic activity, 
Prss14 is further cleaved at Arg614 in autocatalytic fashion and 
converted to two-chain active protease (List et al., 2006). The 
active Prss14 is tightly regulated by its cognate inhibitors, 
hepatocyte growth factor activator inhibitor 1 and 2 (HAI-1 and 
HAI-2) (Lin et al., 1999; Szabo et al., 2008). In addition, a cleavage 
at Lys189 or Lys204 occurs and releases the ectodomain containing 
2 CUB domains, 4 LDLRA repeats, and protease domain from cell 
surface (List et al., 2006). After this shedding, Prss14 N-terminus 
including short stem region, transmembrane domain, and intracellular 
domain remains in the membrane. Ectodomain shedding is induced by 
various stimuli such as serum (Benaud et al., 2001), PMA (Kim et al., 
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2005), TGF-β (Lee et al., 2014), hypoxia (Kim et al., 2010), and 
acidic buffer (Tseng et al., 2017). The ectodomain is cleaved by 
tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17) 
upon PMA and TGF-β, showing that knockdown of TACE 
significantly inhibited the ectodomain shedding (Cho et al., 2017; Lee 
et al., 2014). As well as TACE activity, serine protease activity is 
closely linked to shedding process because the Prss14 catalytic 
inactive mutants does not undergo ectodomain shedding in acidic 
buffer (Tseng et al., 2017) and serine protease inhibitors also reduce 
the Prss14 shedding (Cho et al., 2005; Kim et al., 2005). In PMA-
induced shedding, Prss14 activation and ectodomain shedding are 
induced after rearrangement of actin cytoskeleton and translocation 
of Prss14 to the cell-cell contact through direct interaction between 
its intracellular domain and filamin, indicating the roles of intracellular 
domain in translocation, activation, and shedding (Kim et al., 2005). 
Besides these roles, function of intracellular domain has not been 
studied. 
Some membrane proteins undergoing ectodomain shedding is 
processed by regulated intramembrane proteolysis (RIP) (Brown et 
al., 2000; Lal and Caplan, 2011). RIP is typically followed by initial 
ectodomain shedding and generates the soluble intracellular domain 
(ICD). This generated ICD functions as a signaling molecule in 
cytosol or a transcriptional regulator after translocation to the 
nucleus. (Brown et al., 2000). 
In this study, I report the biological function of Prss14 
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intracellular domain in cancer metastasis. I show that SPPL2b cleaves 
N-terminal fragment of Prss14 followed by PMA-induced 
ectodomain shedding and generates PICD, which promotes migration, 








427.1.86 (Cho et al., 2001), MCF7, and HEK293T cells were 
maintained in DMEM (Gibco) with 10% FBS (Gibco) and 1% 
penicillin/streptomycin (P/S) (Gibco). CHO-K1 cells were 
maintained in F-12 nutrient mixture medium (Gibco) with 10% FBS 
and 1% P/S. 4T1 cells were maintained in DMEM (Welgene) with 10% 
FBS and 4mM L-glutamine (Welgene), and 1% P/S. To generate the 
SPPL2b knockdown 427.1.86 cell lines, two constructs containing 
SPPL2b RNAi and selected more effective construct (pSUPER-
SPPL2b-2). The pSUPER-SPPL2b-2 was transfected into 427.1.86 
cells with pcDNA3 vector. After growing in the presence of 800 g/ml 
G418 (Welgene), clones derived from single cells in 96 well were 
tested for their SPPL2b expression in RNA level with qPCR. For 
Flag-N55 cell lines, p3XFlag-Prss14 N55 was transfected into 
427.1.86 cells and selected with 800 g/ml G418. Clones derived 
from single cells in 96 well were tested for their Flag-N55 
expression in protein level by western blot analysis with anti-Flag 
antibody. For control cell lines, pSUPER vector (CONT) and p3XFlag 
vector (VEC) were transfected into 427.1.86 cells. Lipofectamine 
PLUS Transfection Reagent (Thermo Fisher Scientific, 11514-015) 
was used for all transfection experiments. Cells were cultured at 





Plasmid and siRNA 
The PCR fragments were cloned into the NotI/BamHI sites of the 
p3XFlag-CMV10 vector (Sigma): full length Prss14, amino acids 1–
55, 1–149, 1–162, and 1–213. All Prss14 constructs were designed 
to be in-frame with an N-terminal Flag tag (Fwd: 5'-
AGAGCGGCCGCAATGGGTAGCAAT-3’, N55 Rev: 5'-
ACAGGATCCCCAAGCGCCTGGGGC-3', N149 Rev: 5'-
ACAGGATCCCTCACTGAAGGCAGTT-3', N162 Rev: 5'- 
ACAGGATCCGGGGATGCTGAACTC-3', N213 Rev: 5'- 
TGTGGATCCGCTGTTGTCCTGAGT-3', and Wild type Rev: 5'-
ACAGGATCCCTATACCCCAGTGTG-3'). Human SPPL2b cDNA 
was purchased from OriGene. SPPL2b C-terminally tagged with HA 




AGGCGCCAGG-3’. Flag-Prss14G73A construct was generated by 
PCR mutagenesis using p3XFlag-Prss14 and QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent) for amino acid substitutions 
according to the manufacturer’s instructions. To generate pSUPER-
SPPL2b-2, a pair of oligonucleotides containing a target sequence in 




GGCTGCTCGGTTTTTA-3’ and Rev: 5’- 
TCGATAAAAACCGAGCAGCCTCCAAGTGATCTCTTGAATCACT





Cells grown on gelatin coated slide cover were fixed with 3.7% 
paraformaldehyde in PBS for 10 min, permeabilized with 0.1% 
TritonX-100 in PBS (PBS-T) for 30 min, and incubated in blocking 
solution (10% goat serum, 1% gelatin, and 0.1% TritonX-100 in PBS) 
for 30 min. After washing with PBS-T, samples were treated with 
primary antibody in blocking solution for 1 h. The following primary 
antibodies were used: rabbit polyclonal anti-Prss14 C-terminus, 
rabbit polyclonal anti‐Prss14 N-terminus (Cho et al., 2001), mouse 
monoclonal anti-Flag (clone M2, Sigma, CP2983), rabbit polyclonal 
anti-HA (Santa Cruz Biotechnology, sc-805), mouse monoclonal 
anti-E-cadherin (clone 36, BD Biosciences, 612131), and mouse 
monoclonal anti-Vimentin (clone V9, Sigma-Aldrich, V6389). Cells 
then were washed with PBS-T and incubated with FITC- or 
TRITC-conjugated secondary antibodies (Jackson ImmunoResearch, 
711-095-152, 715-095-150, 711-025-152, and 715-025-150) 
for 50 min. For actin staining, rhodamine-phalloidin (Molecular 
Probe, R415) was used. For EMT marker detection, cells were fixed 
on 2 days after seeding in growth medium. Finally, the coverslips 
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were mounted with DAPI (VECTASHIELD, H-1500) and observed 
under the fluorescence microscope (Axioplan200 M, Carl Zeiss). 
Images were processed in Photoshop CS6 (Adobe). 
 
 
Western blot and immunoprecipitation analysis 
Cells were incubated with 20 M TAPI-0 (Calbiochem, 579050) 
for 2 h or 10 M (Z-LL)2ketone (Calbiochem, 421050) for 6 h in 
serum free medium. Then cells were incubated with 1 M PMA 
(Sigma, P1585) for another 2 h. For control, diluent DMSO was 
treated. Cells were lysed with lysis buffer (50 mM HEPES (pH7.4), 
150 mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 1 mM EDTA 
in the presence of protease inhibitors, leupeptin, aprotinin, and 
pepstatin. Immunoprecipitation of Prss14 N-terminus was 
performed by antibodies and protein A Sepharose bead mixtures for 
2 h, at 4°C. The immunoprecipitates were resuspended in LDS sample 
buffer and reducing agent (Invitrogen). Transfected cells were lysed 
with the lysis buffer and prepared in LDS sample buffer and reducing 
agent. After incubating for 10 min at 70°C, samples were resolved in 
a 4-12% NuPAGE gradient gel (Invitrogen, NP0335PK2). 10% 
trichloroacetic acid (TCA)-precipitates from medium were dissolved 
in SDS sample buffer under recuing condition and resolved in 9% 
SDS-PAGE gel. Samples were subjected to western blot analysis 
with using Enhanced Chemiluminescence reagents (Supersignal West 
Femto, Thermo, 34095). The following primary antibodies were used: 
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rabbit polyclonal anti-matriptase (Millipore, IM1014), mouse 
monoclonal anti-β-tubulin (clone TUB2.1, Sigma, T4026), Rabbit 
polyclonal anti-Laminin A/C (Cell Signaling, 2032), mouse 
monoclonal mAb5 (Cho et al., 2001), rabbit polyclonal anti-Prss14 
N-terminus, rabbit polyclonal anti-human Prss14 N-terminus, 
mouse monoclonal anti-Flag, rabbit polyclonal anti-HA, mouse 
monoclonal anti-E-cadherin, and mouse monoclonal anti-Vimentin.. 
 
 
RNA extraction and quantitative PCR 
Total RNA was extracted using TRIzol (Thermo Fisher Scientific) 
according to the manufacturer's recommendations. Reverse 
transcription reactions were performed with Superscript III Reverse 
Transcriptase (Thermo Fisher Scientific, 18080093). The primers 
sequences used for this study are listed in Resources Table. PCR 
amplifications were performed with TaqMan Gene Expression Master 
Mix (Thermo Fisher Scientific, 4369016) on StepOnePlus Real-
Time PCR System (Applied Biosystems). 
 
 
RNA-sequencing and data analysis 
427.1.86-SPPL2b-knockdown control cells (CONT) and 
SPPL2b-knockdown cells (SP2bKD-10) were incubated in serum 
free medium, followed by another 2 h with or without 1 μM PMA. 
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After treatment with PMA, cells were washed with PBS and total RNA 
was extracted using TRIzol. p3XFlag vector or p3xFlag-N55 was 
co-transfected with GFP vector into SP2bKD-10 cells. After 24 h 
of transfection, GFP-positive cells were sorted using FACSAria II 
(BD Bioscience) (EGFP positive cells of 93% and 88% for KD/GFP 
and KD/GFP+N55, respectively). The collected GFP-positive cells 
were immediately lysed with TRIzol and RNAs were extracted. 
Quality control of extracted RNA was performed using Agilent 2100 
BioAnalyzer with RNA Integrity Number (RIN) value greater than 9. 
RNA-seq was performed by TheragenEtex Bio Institute (Suwon, 
Korea) using with Illumina HiSeq 2500 paired-end RNA sequencing. 
Reads were aligned with Tophat (v2.1.1) and Fragments per kilobase 
of exon per million reads (FPKMs) were calculated using Cufflinks 
(v2.1.1). Cuffdiff (v2.1.1) was used for normalization. Before 
logarithmic processing, 0.000001 was added to FPKM values to all 6 
samples and analyzed in density plots, 0.001 was chosen for FPKM 
cutoff to remove genes with no expression. To screen PICD target 
genes, we filtered out uncharacterized genes without known function 
and DEG analysis was performed pairwise. DEGs in both conditions 
were selected with p-value threshold of 0.1. Among these genes, 
genes with only the same directional changes in both DEG analysis 
were considered for further selection. DEG analysis was performed 
using edgeR (Robinson et al., 2010) . Final PICD target gene list 






Network and cellular process analysis 
For network analysis of PICD target genes, STRING (Szklarczyk 
et al., 2015) was used. STRING predicted protein-protein 
interactions including physical interactions, as well as functional 
interactions from automated text-mining and computational 
predictions. Pathway Studio (Nikitin et al., 2003) based on in-depth 
literature mining analyzed the association between target genes and 
cell migration and invasion process (p<0.001). Promoter binding sites 
within PICD target genes of transcription factors were searched 
using ENCODE (Consortium, 2012).  
 
 
Wound healing assay and invasion assays 
For wound healing assays, cell monolayers were maintained in 
serum-free medium for 12 h and scratched using a P200 pipet tip. 
Cells were washed to remove cell debris and incubated in 1% serum-
containing medium for 24 h. Photographs were taken at 0 and 24 h 
after wounding using Axiovert 200M and the area covered by 
migrating cells was determined by the ratio of scratch area at 0 h to 
scratch area at 24 h using ImageJ Software. Invasion assay was 
performed using a BioCoat Matrigel Invasion Chamber (Corning, 
354480) according to the manufacturer’s instructions. Cells were 
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maintained in serum-free medium for 12 h and 3×105 cells were 
seeded in serum-free medium into the upper chamber. The lower 
chamber was filled with DMEM containing 2% serum with or without 
1 M PMA. After 24 h of incubation, the cells on the upper surface of 
the membrane were removed using cotton swabs. The invaded cells 
on the lower surface of the membrane were fixed with 100% 
methanol for 10 min and stained with 0.2% crystal violet for 5 min. 
The invaded cells were counted under Axioimager M1 and fifteen 
fields were counted. The total number of cells was divided by the 
number of counted field in each assay. 
 
 
Cell scattering assay 
Flag vector and Flag-N55-expressing cells were seeded at a 
low density on 60mm dishes in triplicate and were allowed to grow 
in growth medium for 2 days. Brightfield images were taken at 200x 
magnification using fluorescence microscope (Axioplan200 M, Carl 
Zeiss). Cells were counted as the scattered when cells lost contact 
with neighboring cells and exhibited a migrating phenotype. More 
than 50 images were randomly selected. At least 700 cells were 





Data analyses using TCGA 
TCGA data were downloaded using the Broad Institute’s Firehose, 
web portal site that has been developed aiming to deliver automated 
analyses of the TCGA data to general users. We used Level 3 
normalized RNA-seq data from the January 28, 2016 standard data 
run (https://doi.org/10.7908/C11G0KM9) (Center, 2016). 
Association between PICD target gene set and PRSS14 expression in 
breast cancer patients was analyzed using Gene Set Enrichment 
Analysis (GSEA v3.0, available online: 
http://www.broad.mit.edu/gsea/) (Subramanian et al., 2005). For 
expression correlation analysis, expression values of all patients 
were drawn in scatter plots with linear interpolation curves between 
the two genes. The correlation coefficient r values between two 
genes were calculated using Pearson correlation and unpaired two-
tailed students t-test was performed. For the 5 years survival rate, 
Kaplan-Meier survival analysis was used using TCGA breast cancer 
data excluded data whose contacts were lost in 5 years. The p values 
were calculated using a Log-rank (Mantel-Cox) test and the hazard 






N-terminal of Prss14 is localized in the nucleus 
Prss14 underwent multiple posttranslational processing and I 
wanted to know the cellular localization of two ends of the protein 
after this processing. The N-terminal and C-terminal region were 
detected in the normal culture condition using 427.1.86 thymoma cell 
expressing Prss14 endogenously. When the antibody binding to the 
extracellular part (C-terminus) showed the membrane staining, 
located in the cell-cell contacts, the antibody binding to the 
intracellular part (N-terminus), interestingly, showed nuclear 
staining (Fig. 4A). Both membrane staining and nuclear staining were 
disappeared Prss14-knockdown 427.1.86 cells, validating the 
specificity of these antibodies (Fig. 4B). The expression of Prss14 
in knockdown cells was shown in Fig. 4C. Nuclear localization of the 
Prss14 N-terminus was further verified with ectopically expressing 
the Flag-tagged intracellular domain (N-terminal 55 amino acids) in 
COS7 cells (Fig. 5). These findings suggest that the Prss14 N-
terminus maybe detach from the plasma membrane and translocate 
to the nucleus. 
 
 
Ectodomain shedding induces PICD generation 








Figure 4. C-terminus and N-terminus of Prss14 show different 
cellular localization in 427.1.86 cells 
(A) Cellular localization of endogenous Prss14 in 427.1.86 cells. 
Anti-Prss14 antibodies (green) against extracellular parts (anti-C 
antibody) or intracellular parts (anti-N antibody) were used. Scale 
bars, 20 m. (B) Prss14 was stained with two kinds of anti-Prss14 
antibodies in 427.1.86 cells (427) and 427.1.86-Prss14 knockdown 
cells (427KD). Scale bars, 20 m. (C) Western blot analysis of 













Figure 5. Cellular localization of Flag-tagged Prss14 N-terminus  
COS7 cells were transfected with Flag-N55 and stained with anti-
Flag antibody. Localization of the Flag-tagged Prss14 N-terminus 













were cleaved by intramembrane proteases and generated the 
intracellular domain to translocate to the nucleus through RIP process 
(Brown et al., 2000), it was hypothesized that the nuclear staining of 
the Prss14 N-terminus was resulted from RIP. Prss14 is shed by 
various stimuli including serum (Benaud et al., 2001), PMA (Kim et 
al., 2005), TGF- (Lee et al., 2014), hypoxia (Kim et al., 2010), and 
acidic buffer (Wang et al., 2009). Generally, RIP is proceeded by 
ectodomain shedding (Brown et al., 2000) and the PMA, one of the 
stimuli of Prss14 ectodomain shedding, was tested to be able to 
induce RIP.  
    To investigate the effect of PMA on the N-terminal 
fragmentation of Prss14, the localization of N-terminus was detected 
using anti-Prss14 N-terminus antibody (N-antibody). In PMA-
treated 427.1.86 cells, the nuclear staining Prss14 was increased 
compared to the cells under serum deprivation (Fig. 6). Next, to 
verify the presence of the N-terminal fragment, western blot 
analysis following immunoprecipitation with N antibody was 
performed. PMA treatment enhances not only shed Prss14 (Prss14-
S’), but also a smaller fragment with a molecular weight (~14 kDa, 
Fig. 7A). These results suggest that Prss14 is processed by another 
proteolysis called RIP and the cleaved Prss14 intracellular domain 
(PICD) is translocated to the nucleus. 
    To address whether PMA-mediated ectodomain shedding is 
critical for PICD generation, the shedding was inhibited and observed 









Figure 6. PMA treatment enhances the nuclear localization of Prss14 
N-terminus 
427.1.86 cells were deprived serum for 2 h and treated with 1M 
PMA for another 2 h. Cellular localization of Prss14 N-terminus was 














Figure 7. PMA-induced Prss14 ectodomain shedding induces 
generation of the PICD 
(A) Endogenous PICD detected by immunoprecipitation with anti-N 
antibody in 427.1.86 cells in the absence or presence of PMA. Anti-
N antibody was used for western blot. (B) Western blot analysis of 
PICD immunoprecipitated with anti-N antibody in 427.1.86 cells 
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Figure 8. PICD generation is also observed in MCF7 human breast 
cancer cell line 
 MCF7 human breast cancer cells were subjected to 
immunoprecipitation with anti-hN antibody against human Prss14 
N-terminus. Normal rabbit serum (CS) was used for negative control. 









is mediated by TACE (Cho et al., 2017). The TACE inhibitor, TAPI-
0, reduced PMA-induced shedding and concomitantly the PICD 
generation (Fig. 7B). This result showed that ectodomain shedding 
is required and prerequisite step for EICD generation. 
   The PICD generation was also observed in MCF7 human breast 
cancer cell line. PICD that had similar molecular weight tobserved in 
427.1.86 cells was increased by PMA treatment, showing that the 
generation of EICD was not specific phenomenon for 427.1.86 cells 
(Fig. 8). Taken together, these data suggest that Prss14 generates 
PICD in an ectodomain shedding-dependent manner.  
 
 
SPPL2b is responsible for intramembrane proteolysis of 
Prss14 N-terminus 
Among the intramembrane proteases known for RIP, SPPLs 
cleave type II-oriented transmembrane proteins (Fluhrer et al., 
2009). It was investigated that SPPLs were involved in the cleavage 
of Prss14, a type II transmembrane protein. When sequences 
containing the transmembrane domain and about twenty residues 
before and after the transmembrane domain of Prss14 and known 
SPPLs’ substrates, there were some conserved residues, leucines 
and glycine in the transmembrane domain (Fig. 9A). In addition, the 
SPPLs-specific inhibitor, (Z-LL)2ketone, reduced the amount of 










Figure 9. SPPLs are involved in the cleavage of Prss14 
(A) Sequence alignment of regions containing predicted 
transmembrane domains of Prss14 and other known SPPL substrates. 
(B) 427.1.86 cells were treated with PMA in the absence or presence 
of SPPLs inhibitor, (Z-LL)2ketone and subjected to 
immunoprecipitated with anti-N antibody. Normal rabbit serum (CS) 
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Figure 10. SPPL2b is localized at the plasma membrane 
CHO-K1 cells were transiently transfected with SPPL2b-HA and 













Figure 11. Knockdown of SPPL2b reduces nuclear localization of PICD 
(A) mRNA level of SPPL2b in SPPL2b-knockdown cell lines 
(SP2bKD-10 and -16)  was detected by real time-PCR. The 
relative values were normalized to GAPDH signals as shown in the 
graphs. (B) Prss14 was stained with two kinds of anti-Prss14 
antibodies in control CONT and SP2bKD-10 cells. Arrow indicates 
nuclear localization of PICD and arrow head   indicates decreased 














Figure 12. PICD generation is reduced in SPPL2b-knockdown cells 
even in PMA treatment 
PICD was immunoprecipitated in SP2bKD cells and analyzed by 
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Next, I investigated which SPPL member was responsible for 
PICD generation. SPPL members have different cellular localization 
and only SPPL2b is found in the plasma membrane (Friedmann et al., 
2006). Because the PICD was generated following ectodomain 
shedding on the cell surface, it was speculated that the plasma 
membrane was the place occurring RIP and SPPL2b might be the 
protease to cleave Prss14 NTF. As expected, SPPL2b localized at 
the plasma membrane in CHO-K1 cells transfected with HA-tagged 
SPPL2b (Fig. 10). To test that the SPPL2b is involved in generation 
of PICD, the nuclear localization of PICD was observed in SPPL2b-
knockdown 427.1.86 cells (SP2bKD). The reduced mRNA level of 
SPPL2b in SP2bKD cells was shown in Fig. 11A. Nuclear localization 
of PICD was significantly diminished in SP2bKD cells, however, 
membrane localization of C-terminus was still observed in these 
cells (Fig. 11B). In addition, PICD was decreased compared to control 
cells even though PMA-induced ectodomain shedding normally 
occurred in these cells (Fig. 12) 
To further confirm that SPPL2b indeed cleaves Prss14, SPPL2b 
and Prss14 were co-transfected in HEK293T cells. The expression 
of SPPL2b increased the amount of PICD in a dose-dependent 
manner in HEK293T cells (Fig. 13). These results directly indicate 
that SPPL2b cleaves Prss14. 
To understand the relationship between ectodomain shedding and 
SPPL2b-mediated cleavage, we expressed Flag-tagged wild-type 
and truncated Prss14, Flag-N55, N149, N162, and N213 in 
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HEK293T cells (Fig. 14A). Cells expressing Flag-WT and Flag-
N213, containing more amino acid sequences than shedding cleavage 
positions, generated more PICD than Flag-N149- and Flag-N162-
expressing cells (Fig. 14B), suggesting that intramembrane cleavage 
of Prss14 by SPPL2b is tightly coupled to ectodomain shedding event. 
As shown in Fig. 9A, there are conserved residues between 
substrates of SPPLs. I-TASSER server predicted that the structure 
of transmembrane domain of Prss14 adopted the -helical 
conformation in which peptide bonds were hard to access by 
proteases. It has been shown that the helix-destabilizing residues 
reducing the-helical content of transmembrane domain are 
required for processing by intramembrane proteases (Fluhrer et al., 
2012; Lemberg and Martoglio, 2002). Based on this, we determined 
if the conserved residues, Gly73 functioned as helix breaker for 
intramembrane cleavage by SPPL2b using Prss14 mutants with 
replacement of Gly73 to Ala (G73A). The PICD level was 
considerably reduced when the G73A mutant was co-expressed with 
SPPL2b (Fig 15), demonstrating that Gly73 is important for 
intramembrane proteolysis by SPPL2b. 
 
 
PICD participates in transcriptional regulation 
The nuclear localization of PICD suggested a possible role in 
regulating gene transcription. To investigate target genes regulated 








Figure 13. Expression of SPPL2b increases PICD in dose-dependent 
manner 
Western blot analysis of PICD by Flag antibody from HEK293T cells 
transfected with Flag-Prss14 and increasing amounts of SPPL2b-
HA. An arrowhead indicates SPPL2b. The graph shows the relative 
amount of PICD as fold change compared to PICD of cells transfected 
with 0.25 g of Prss14. PICD band intensities were normalized to 
SPPL2b-HA and tubulin band. The graph is represented as the mean 
± SEM from three independent experiments. Statistical analysis was 
performed using an unpaired two-tailed student t-test. *p < 0.05, 
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Figure 14. Ectodomain shedding is required for SPPL2b-mediated 
cleavage of Prss14 
(A) Schematic diagrams of Prss14 domain structure and the 
constructs used. (B) Flag-tagged Prss14 constructs were 
transiently co-transfected with or without SPPL2b-HA to HEK293T 
cells and PICD was detected by western blot analysis. The graph 
shows the relative amount of PICD as fold change compared to PICD 
of Flag-N149. PICD band intensities were normalized to SPPL2b-
HA and tubulin band. The graphs is represented as the mean ± SEM 
from three independent experiments. Statistical analysis was 
performed using an unpaired two-tailed student t-test. *p < 0.05, 











































































































Figure 15. Gly73 residue is important for SPPL2b-mediated cleavage 
of Prss14 
(A) Structure modeling of transmembrane domain of Prss14.  
Schematic diagrams of Prss14 domain structure and the constructs 
used. (B) Western blot analysis of PICD from HEK293T cells 
transiently co-transfected with SPPL2b-HA and Flag-Prss14 (WT) 
or Flag-Prss14-G73A (G73A). The graph shows the relative 
amount of PICD as fold change compared to PICD of wildtype. PICD 
band intensities were normalized to SPPL2b-HA and tubulin band. 
The graph is represented as the mean ± SEM from three 
independent experiments. Statistical analysis was performed using 







































































Figure 16. RNA samples preparation for RNA-seq 
(A) The schematic diagram describes how to prepare RNA samples 
for RNA-seq. (B) SP2bKD cells were transfected with GFP vector 
and Flag-vector or GFP vector and Flag-N55 for 24 h and GFP-
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Cellular process  Promoter binding$ 
Migration Invasion EMT 
TNF 
pathway 
 FOS ATF3 RPDM1 
  Up-regulated genes         
ABCA12 
ATP-binding cassette, sub-family A (ABC1) 
member 12 
  O   O   
ANKRD22 ankyrin repeat domain 22      O   
ATF3 activating transcription factor 3 O O O O  O O O 
CEACAM19 
carcinoembryonic antigen-related cell  
adhesion molecule 19 
        
CXCL2 chemokine (C-X-C motif) ligand 2 O O  O  O O O 
CXCL3 chemokine (C-X-C motif) ligand 3 O   O     
DAGLA diacylglycerol lipase, alpha      O O  
EFEMP2 
epidermal growth factor-containing  
fibulin-like extracellular matrix protein 2 
O O O   O O  
EGR2 early growth response 2    O  O O  
EGR3 early growth response 3   O O     
FOS FBJ osteosarcoma oncogene O O O O  O O  
FOXO1 forkhead box O1   O   O   
HIVEP3 
human immunodeficiency virus type I  
enhancer binding protein 3  
     O   
LHFPL2 lipoma HMGIC fusion partner-like 2      O   
LONRF1 
LON peptidase N-terminal domain and ring  
finger 1 
     O O  
MMP13 matrix metallopeptidase 13 O O O O  O   
NABP1 nucleic acid binding protein 1      O O  
NR4A1 
nuclear receptor subfamily 4, group A,  
member 1 
O O O O  O   
PRDM1 PR domain containing 1, with ZNF domain O O  O  O   
RND1 Rho family GTPase 1 O O O   O O  
SAT1 spermidine/spermine N1-acetyl transferase 1 O O O O  O O  
STK40 serine/threonine kinase 40      O O  
TNF tumor necrosis factor O O O O  O   
TNFRSF1B 
tumor necrosis factor receptor superfamily,  
member 1b 
  O  O   
TNFSF15 
tumor necrosis factor (ligand) superfamily,  
member 15 
O O    O O O 
USP43 ubiquitin specific peptidase 43      O   
VGF VGF nerve growth factor inducible   O   O O  
  Down-regulated genes         
UBC Ubiquitin C       O O 
† ‡ † 
† 
Gene symbols in bold encode transcription factors 
Cellular process that each gene is involved was analyzed by Pathway Studio† and literature search‡ 























ABCA12 O (Kan et al., 2012) 
ANKRD22   
ATF3 O (Yin et al., 2010) 
CEACAM19   
CXCL2   
CXCL3   
DAGLA   
EFEMP2 O (Zhang et al., 2017) 
EGR2   
EGR3 O (Chaudhury et al., 2016) 
FOS O 
(Eger et al., 2000; Gao et al., 2015; Shao et al., 
2014) 
FOXO1 O (Dong et al., 2017) 
HIVEP3   
LHFPL2   
LONRF1   
MMP13 O (Huang et al., 2016; Shan et al., 2018) 
NABP1   
NR4A1 O (Hedrick and Safe, 2017; Zhou et al., 2014) 
PRDM1   
RND1 O (Okada et al., 2015) 
SAT1 O (Wang et al., 2017) 
STK40   
TNF O (Chua et al., 2007; Wang et al., 2013) 
TNFRSF1B   
TNFSF15   
USP43   
VGF O (Hwang et al., 2017) 
UBC   
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from three sets of conditions (Fig. 16A). First, to see the genes 
induced by RIP following PMA-mediated shedding, RNA from non-
treated 427.1.86 cells (CONT) was compared with that from PMA-
treated cells (CONT+PMA) (group A). Second, to exclude SPPL2b-
independent PMA effects, RNAs from SPPL2b-knockdown cells 
showing reduced PICD generation (SP2bKD-10, KD) and PMA-
treated SP2bKD-10 cells (KD+P) were compared (group B). Finally, 
to determine the direct effect of PICD, RNAs from SP2bKD-10 cells 
transfected with a GFP vector (KD/GFP) and those from SP2bKD-
10 cells co-transfected with a GFP vector and Flag-N55 
(KD/GFP+N55) were used (group C). RNAs from group C were 
prepared from GFP-positive sorted cells (Fig. 16B). 
Fig. 17 described how I analyzed RNA-seq results to identify 
PICD target genes. We first filtered out genes with no expression in 
all 6 samples with the FPKM cutoff of 0.001 based on the expression 
profiles and analyzed the differentially expressed genes (DEGs). The 
results showed that there were 820 genes in group A and 671 genes 
in group C (p < 0.1). The 128 genes common to groups A and C were 
further reduced to 78 genes by considering those exhibiting the same 
directional changes by PMA and N55. We next removed the DEGs of 
group C (p > 0.05) to exclude SPPL2b-independent PMA effects. 
Finally, 28 genes that satisfied all these stringent criteria were 





PICD target genes are involved in cancer-associated cell 
processes 
To investigate the functional interactions network between 
target genes, STRING, a web-based protein-protein association 
database was used. In both the mouse and human databases, the 
network of target genes included three subnetworks, FOS-, TNF-, 
and UBC-centered subnetworks comprised of transcription factors 
(ATF3, EGR2, EGR3, FOS, FOXO1, and NR4A1), cytokines (CXCL2, 
CXCL3, and TNF), and genes in the ubiquitin proteasome pathway 
(LONRF1, UBC, and USP43), respectively (Fig. 18 and Fig. 19). 
Finally, we examined whether the target genes of PICD are 
involved in cell migration, invasion, and EMT, which are the known 
functions of Prss14 (Lee et al., 2010; Szabo et al., 2011; Tsai et al., 
2014). By mining the publications, I found 12 genes to induce EMT 
(Table 2). Pathway Studio showing that target genes are associated 
in which cellular processes and signaling pathway presented that 11 
of 28 genes were known to be involved in cell migration and invasion. 
PICD target genes were also involved in many cellular processes 
associated with cancer progression, such as immune response, cell 
proliferation, and angiogenesis (Table 3). Furthermore, many target 
genes (13 of 28) were associated in the TNF pathway that was one 
of the center molecules in the network (Table 1). Because 8 of the 
final targets are known transcription factors, we investigated if PICD 
induces transcriptional activation of its targets indirectly through 



























Figure 18. Network analysis of PICD target genes with mouse 
database 
Network analysis of 28 PICD target genes using STRING with mouse 
database. Genes with no links are not presented. Interactions are 

















Figure 19. Network analysis of PICD target genes with human 
database 
Network analysis of 28 PICD target genes using STRING with human 
database. Genes with no links are not presented. Interactions are 











(Consortium, 2012) provided information for only three transcription 
factors, ATF3, FOS, and PRDM1. ENCODE analysis showed that 24 
of PICD target genes contained the binding sites for FOS (Table 1). 
Additionally, 14 targets contain ATF3 and 4 targets contain PRDM1 
binding sites (Table 1). PICD may induce transcriptional activation of 
specific transcription factors, which in turn regulates the expression 
of genes involved in cell migration, invasion, EMT, and TNF-related 
pathways. 
 
PICD is sufficient to enhance cell migration, invasion, and 
EMT 
To validate the computational analysis showing the potential 
roles of PICD, we tested if PICD promotes cell migration and invasion 
using PICD-overexpressing 427.1.86 cells (Flag-N55-1 and -5, 
Fig. 20A). We found that Flag-N55 overexpression promoted cell 
migration ability by up to 3-fold comparing to in the control group in 
the wound healing assay (Fig. 21). Additionally, overexpression of 
Flag-N55 significantly enhanced cell invasion through Matrigel (Fig. 
22). These results indicate that PICD itself is sufficient to promote 
migration and invasion. Although SP2bKD cells lost the ability to 
induce migration upon PMA stimulation, expression of Flag-N55 
recovered the migration ability even without PMA stimulation (Fig. 
20B and Fig. 23). PMA-induced invasion through Matrigel was 
abolished in SP2bKD cells, but this impaired cell invasion was 









Figure 20. Flag-N55 is stably transfected in 427.1.86 cells and 
transiently expressed in SP2bKD-10 cells 
(A) Western blot analysis of 427.1.86-Flag-N55 cell lines with 
anti-Flag antibody. (B) SP2bKD-10 cells were transiently 
transfected with Flag-N55. After 24 h of transfection, expression of 
Flag-N55 was analyzed by Western blotting with anti-Flag antibody. 
















































   
  
   






















Figure 21. Cell migration is increased in Flag-N55-overexpressing 
cell 
Wound healing assay using 427.1.86 cells stably expressing Flag-
N55. Representative brightfield images at the time of 0 h and 24 h 
were shown. Graph shows the recovered area by migrated cells for 
24 h. Cells in six different microscopic fields were examined from 
three independent experiments. Data are presented as a mean ± SEM 
(error bars). Statistical analysis was performed using an unpaired 

















Figure 22. Cell invasion is increased in Flag-N55-overexpressing cell 
Invasive activity of Flag-N55 expressing cells was investigated 
using Matrigel invasion assay. Representative brightfield images of 
invaded cells were shown. Graph shows migrated cells to the outer 
chamber for 24 h. Cells in fifteen different microscopic fields were 
examined from three independent experiments. Data are presented 
as a mean ± SEM (error bars). Statistical analysis was performed 
using an unpaired two-tailed student t-test. *p < 0.05, **p < 0.01, 
















Figure 23. PICD generation by SPPL2b is required for cell migration 
Wound healing assay using SP2bKD cells. Representative brightfield 
images at the time of 0 h and 24 h were shown. Graph shows the 
recovered area by migrated cells for 24 h in the presence or absence 
of PMA. Flag-N55 was transiently transfected for 24 h and used for 
wound healing assay. Graph shows the recovered area by migrated 
cells for 24 h. Cells in six different microscopic fields were examined 
from three independent experiments. Data are presented as a mean 
± SEM (error bars). Statistical analysis was performed using an 
unpaired two-tailed student t-test. *p < 0.05, **p < 0.01, ***p < 















































































Figure 24. PICD generation by SPPL2b is required for cell invasion 
(A) Invasive activity of SP2bKD cells was measured using Matrigel 
invasion assay. Representative brightfield images of invaded cells 
were shown. Graph shows migrated cells to the outer chamber for 24 
h in the presence or absence of PMA. (B) SP2bKD-10 cells were 
transfected with Flag-N55. 24 h after transfection, Matrigel invasion 
assay was performed. Cells in fifteen different microscopic fields 
were examined from three independent experiments. All data are 
presented as a mean ± SEM (error bars). Statistical analysis was 
performed using an unpaired two-tailed student t-test. *p < 0.05, 














Figure 25. PICD causes the morphological change 
Representative brightfield images of 427.1.86 cells stably expressing 
Flag vector or Flag-N55. Graph shows the percentage of scattered 
cells over the total number of cells in each field. At least 745 cells in 
50 fields were counted per condition. Scale bars, 50 m. Data are 
presented as a mean ± SEM (error bars). Statistical analysis was 
performed using an unpaired two-tailed student t-test. *p < 0.05, 















Figure 26. PICD induces the expressional changes of EMT markers 
Representative immunofluorescent images of Flag-N55 cells stained 








the cellular morphology with loosened cell-cell adhesion and a more 
elongated and scattered phenotype compared to the cell expressing 
Flag vector in normal culture conditions (Fig. 25). While the epithelial 
marker E-cadherin was decreased in Flag-N55 cells, the 
mesenchymal marker vimentin was increased (Fig. 26A and Fig. 
26B). Taken together, these results indicate that PICD generated by 
RIP plays important roles in migration, invasion, and EMT, which is 
consistent with the results of RNA-seq analysis. 
 
Expression of PICD target genes correlates with expression of 
PRSS14 in breast cancer patients 
The Prss14 is upregulated in breast cancer patients and its 
upregulation is implicated in poor survival (Kang et al., 2003; Kim et 
al., 2016; Welm et al., 2007). Therefore, the clinical relevance of 
PICD-regulated genes was investigated in breast cancer patients 
using The Cancer Genome Atlas (TCGA). First, gene set enrichment 
analysis (GSEA) was performed with the PICD target gene set and 
TCGA breast cancer dataset separated into high and low PRSS14 
expression. The results showed that PICD target genes were 
significantly enriched in high PRSS14 expression group at the 
stringent false discovery rate (FDR) cutoff of less than 0.05 (NES = 
1.675, FDR = 0.012, Fig. 27). Next, the correlation of expression 
between each target gene and SPPL2B in the high PRSS14 group was 
analyzed to evaluate whether target genes were regulated by 












Figure 27. GSEA using PICD target genes in breast cancer patients 
Enrichment plots of 28 PICD target genes according to PRSS14 
mRNA expression levels by gene set enrichment analysis (GSEA) 
from TCGA breast cancer dataset. NES, normalized enrichment score; 





Enrichment Score (ES) 0.499 




























































Figure 28. Correlation analysis of target gene expression with SPPL2B 
in PRSS14 high TCGA breast cancer patients 
Scatter plots showing correlation between PICD target genes and 
SPPL2B in PRSS14 high TCGA breast cancer patients. r value is 
Correlation coefficient r values between two genes computed using 
Pearson correlation calculations. Two-tailed p values were 
calculated by an unpaired t test. *P < 0.05, ***P < 0.001,****P < 
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levels of both SPPL2B and PRSS14 were high, the expression of 
PICD generation, 9 target genes (CXCL2, DADGLA, EFEMP2, EGF3, 
FOS, NR4A1, RNA1, STK40, and VGF) were also high, showing a 
positive correlation (Fig. 28). Therefore, these results suggest that 
expression of these target genes is regulated by PRSS14 and 
SPPL2B in breast cancer patients. 
 
 
PICD target genes along with PRSS14 are valuable markers of 
ER-negative breast cancer 
The PRSS14 is the critical prognosis marker for ER negative 
breast cancer patients (Kim et al., 2016). I evaluated the relationship 
between PICD and survival of ER-negative breast cancer patients in 
TCGA breast cancer dataset. For this, the survival rate was analyzed 
according to SPPL2B expression which is critical factor of EICD 
generation. The ER-negative and SPPL2Bhigh group showed the 
worst survival outcome (ER(-)SPPL2Bhigh vs. ER(+)SPPL2Blow, 
hazard ratio (HR) = 3.20, p < 0.001, Fig. 29A). In the ER negative 
group, the SPPL2Bhigh groups showed poorer survival than the 
SPPL2Blow groups (ER(-)SPPL2Bhigh vs. ER(-)SPPL2Blow, HR = 
1.88, p = 0.076), ,indicating that high expression of SPPL2B 
determines the survival of ER-negative breast cancer patients (Fig. 
29A). In the ER-negative group, the PRSS14high/SPPL2Bhigh group 
showed the poorest survival pattern, although the results were not 










Figure 29. Survival rate is lower in SPPL2Bhigh breast cancer patients 
than SPPL2Blow 
(A) Kaplan-Meier survival analysis of four breast cancer patient 
groups divided by ER status and then high (hi) and low (lo) SPPL2B 
expression in total TCGA breast cancer patients. (B) ER-negative 
breast cancer patients were divided by expression level of PRSS14 
and SPPL2B. The p values were calculated using log-rank statistics. 



















Figure 30. ER-negative breast cancer patients with high expression 
of PRSS14 and PICD target genes show poorer survival 
Kaplan-Meier survival analysis of ER negative patient groups divided 
by expression level of PRSS14 and EPEMP2 (A), FOS (B), and 
MMP13 (C), respectively. The p values were calculated using log-


















Figure 31. Model for PICD generation and dual function of Prss14 in 







analysis (Fig. 29B). These results suggest that expression of 
SPPL2B and PRSS14 are useful markers for poor prognosis in ER-
negative breast cancer patients. 
Survival analysis was also performed in ER negative groups 
divided by PRSS14 expression and each target gene expression. 
Among the target genes, high expression of FOS, EFEMP2, and 
MMP13 along with high PRSS14 expression led to the worst survival. 
The PRSS14high/FOShigh group showed significantly worse outcomes 
compared to the PRSS14high/FOSlow and PRSS14low/FOShigh groups 
(PRSS14high/FOShigh vs. PRSS14high/FOSlow, HR = 2.86, p < 0.01, 
PRSS14high/FOShigh vs. PRSS14low/FOShigh, HR = 3.21, p < 0.05, Fig. 
30A). Additionally, the PRSS14high/EFEMP2high and 
PRSS14high/MMP13high groups similarly showed the worst outcomes 
among the 4 groups (PRSS14high/EFEMP2high vs. PRSS14low/ 
EFEMP2low, HR = 2.54, p < 0.05 PRSS14high/MMP13high vs. 
PRSS14low/MMP13low, HR = 2.90, p < 0.05, Fig. 30B and Fig. 30C). 
Therefore, a combination of PRSS14 and FOS, EFEMP2, or MMP13 
can be used as an additional prognosis marker for ER-negative 






Here, I demonstrated that the novel proteolytic processing of 
Prss14 by SPPL2b, which generates intracellular fragment, PICD, and 
its roles in regulation of gene expression involved in cancer 
progression. The PICD target genes are involved in cell migration, 
invasion, EMT, and TNF signaling pathway. Overexpression of PICD 
was sufficient to induce cell migration, invasion, and EMT. 
Bioinformatic analysis showed that high expression of PICD target 
genes including FOS, EFEMP2, and MMP13 along with PRSS14 leads 




 RIP of Prss14 leads N-terminal PICD to translocate into the 
nucleus upon shedding 
Prss14 undergoes RIP upon shedding to generate PICD which is 
liberated from the membrane and translocated to the nucleus (Fig. 
4-6). The nuclear localization was observed with 
immunocytochemistry using antibody detecting Prss14 N-terminus 
but the mechanism of its nuclear translocation did not revealed in this 
study. In amyloid precursor protein (APP) that is one of the best 
studied substrate of RIP, intracellular domain is phosphorylated and 
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this phosphorylation is essential for binding to adaptor protein FE65 
and nuclear translocation. Interaction between FE65 and intracellular 
domain modulates transcription of target genes with nuclear protein 
Tip60 (Chang et al., 2006; Kimberly et al., 2001; von Rotz et al., 
2004). Another well-known substrate is Notch. Its intracellular 
domain translocates to the nucleus through the Importin and binds 
to DNA-binding protein CSL following activation of transcription 
(Lubman et al., 2004; Nakahara et al., 2009). Like the APP and Notch, 
how translocation of EICD is regulated as well as which molecules 
participate in the transcriptional regulation needs to be further 
studied. 
The apparent size of PICD detected by immunoprecipitation is 
larger than the expected size. This size difference may result from 
anomalous migration of short fragment or from posttranslational 
modification. It is known that the detergents like SDS can bind more 
preferentially to hydrophobic residues and/or α-helical structure of 
proteins, causing migration inconsistently to expected position in the 
gel (Rath et al., 2009). Prss14 cytoplasmic domain possesses two 
α-helices (Fig. 15A), which is predicted by I-TASSER server 
(Yang et al., 2015) and is likely to be bound with more detergent, 
causing increased apparent size. On the other hand, one possible 
posttranslational modification is SUMOylation. The SUMO modifies 
many nuclear proteins functioned in transcription, chromatin 
structure, and DNA repair and regulates their nuclear localization and 
activity (Johnson, 2004). In PICD sequence, there are two putative 
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SUMOylation sites (Zhao et al., 2014) that can be SUMOylated in 
vitro.  
RIP of Prss14 is mediated by SPPL2b (Fig. 11 and Fig. 12). 
Inhibition of SPPL2b activity or knockdown of SPPL2b reduced PICD 
generation (Fig. 9B and Fig. 12), while forced expression of SPPL2b 
increased it (Fig. 13). Flag-N213 and Flag-FL were more effective 
substrates for SPPL2b than Flag-N149 and Flag-N162 lacking 
sheddase cleavage sites (Fig. 14B). Thus, it seems that removing the 
bulk region of extracellular part is not enough for the SPPL2b-
dependent cleavage. Rather, cleavage at the right position may 
provide a favorable conformational change for access of and cleavage 
by the RIP protease. In addition, helix-destabilizing residue, Gly73, 
was found at the conserved position in transmembrane domains of 
Prss14 and known SPPL2b substrates (Fig. 9A). The transmembrane 
-helices of integral membrane proteins usually prevent the access 
of intramembrane proteases. Presence of Gly73 in the 
transmembrane helix of Prss14 may reduce the α-helical content 
of its transmembrane domain, thus exposing the cleavage site for the 
intramembrane protease (Fluhrer et al., 2012; Lemberg and 
Martoglio, 2002). PICD was not completely inhibited in the cells 
expressing G73A. This also observed in similar studies with Bri2 and 
CD74 (Fluhrer et al., 2012; Huttl et al., 2016). The Bir2 mutant 
replacing all glycines within the transmembrane region to alanines 
showed reduced ICD. Though Bri3 that is close homologue of Bri2 
contains glycine residues in transmembrane, it is not a substrate for 
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SPPL2b (Martin et al., 2009). These results demonstrate that the 
SPPL-mediated cleavage of intramembrane domain is not solely 
determined by the destabilized secondary structure. 
 
 
 PICD can play key multiple roles during metastasis through 
transcriptome changes 
To screen the PICD-regulated genes, RNA-seq analysis was 
done with three different sets of conditions (Fig. 16A). The 
experiments were designed to analyze genes (1) induced by PICD 
after PMA-mediated shedding, (2) not affected by only PMA without 
RIP and, (3) induced directly by PICD in SP2bKD cells. Three sets 
of DEG analyses after removal of genes with not consistent 
expression directionality yield final 28 genes as PICD target gene 
candidate (Table 1). 
The most of target genes were involved in cellular processes 
associated with cancer progression and metastasis, such as immune 
response, cell proliferation, invasion, and angiogenesis (Table 1 and 
3). For the verification of PICD functions, cell migration and invasion 
which were well-known function of Prss14 were tested. Using in 
vitro cell-based assays, it was shown that PICD alone was sufficient 
to enhance cell migration and invasion (Fig. 21-24). 
It is suspected that the PICD-regulated genes may include EMT 
function since Prss14 is necessary and sufficient for EMT (Lee et al., 
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2010). Quick search of online EMT database such as dbEMT (Zhao 
et al., 2015) did not include the most of genes in the final list 28 
genes except MMP13 and TNF. However, literature searches for the 
individual genes revealed the experimental evidences of 12 genes 
that are causing EMT. Furthermore, expression of PICD alone 
induces EMT-like morphological changes (Fig. 25). Flag-N55-
overexpressing cells reveal less expression of pre-EMT markers, 
E-cadherin, and more expression of post-EMT marker, vimentin 
(Fig. 26). 
It is interesting that FOS gene appears as a PICD target gene and 
most of the genes in the final list contain the FOS binding sites. In 
functional network analysis carried out by STRING, FOS behaves as 
a core gene to connect most other transcription factors and also other 
core genes, TNF and UBC (Fig. 18 and Fig. 19). FOS is known for 
directly regulating EMT. FOS can drive mesenchymal morphology as 
well as transcriptional changes of EMT marker genes, such as CDH, 
VIM, and SLUG (Eger et al., 2000; Gao et al., 2015; Mejlvang et al., 
2007; Shao et al., 2014). Other transcription factors, ATF3, EGR3, 
and NR4A1 are also known to be involved in EMT (Chaudhury et al., 
2016; Yin et al., 2010; Zhou et al., 2014). Therefore, it is highly likely 
that FOS is the key transcription factor in PICD target genes driving 
the EMT pathway. 
It was also revealed that genes encoding cytokines in the TNF-
related pathway are the PICD targets (Table 1). These cytokines 
were implicated in various aspects of cancer development and 
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metastasis. They modulate cancer microenvironment for cancer cells 
to escape the immune response (Kitamura et al., 2015; Schreiber et 
al., 2011). Especially, the cytokines in PICD target genes are 
functionally associated with TNF in gene networks from STRING 
(Fig. 18 and Fig. 19). It is well recognized that TNF, a multifunctional 
cytokine, is produced from cancer cells and plays important roles by 
regulating cell survival, EMT, and angiogenesis through various 
signaling pathway in cancer progression and metastasis (Balkwill, 
2009; Wu and Zhou, 2010). Also, TNF functions as a key 
proinflammatory cytokines to promote inflammation that is closely 
linked cancer development (Balkwill, 2009; Balkwill, 2012). 
Interestingly, CXCL2 and CXCL3, chemokines well-known for 
recruiting tumor-associated leukocytes (Galdiero et al., 2013) are 
induced by TNF (Acharyya et al., 2012; Qiao et al., 2016) and play 
important roles in metastasis by exerting proangiogenic effect 
(Acharyya et al., 2012; Sarvaiya et al., 2013; See et al., 2014). 
Taken together, it is evident that PICD promotes cancer 
metastasis by regulating gene expression that involved in various 
processes including invasion, EMT, and immune modulation, although 
further studies are required to examine that these PICD target genes 
indeed function in cancer development and metastasis by PICD. 
 
 




Previously, Prss14 was reported as a significant prognosis 
marker for ER negative breast cancer that has high medical unmet 
need (Kim et al., 2016). Triple negative breast cancer is the most 
aggressive and metastatic subtype and there is no effective targeted 
therapy available at the clinical level (Wahba and El-Hadaad, 2015). 
In this study, I expect to extend the significance of Prss14 as a 
valuable marker for prognosis and therapy of ER-negative breast 
cancer by identifying RIP process. PICD target genes showed 
significant enrichment plot in breast cancer patients with high 
expression of PRSS14 (Fig. 27). Several genes’ expression 
positively correlated with SPPL2B in PRSS14high group (Fig. 28). 
TACE, another factor required for PICD generation, is upregulated in 
triple negative breast cancer (McGowan et al., 2013). Therefore, it 
is speculated that SPPL2Bhigh and PRSS14high group of ER negative 
breast cancer patients can generate more PICD than SPPL2Blow and 
PRSS14low group. 
The critical enzyme for PICD generation, SPPL2B contributes 
survival of PRSS14 expressing ER negative breast cancer patients. 
PRSS14 high and SPPL2B high group showed the poorest survival in ER 
negative patients (Fig. 29). In addition, when PICD target genes, FOS, 
EFEMP2, and MMP13, were highly expressed along with PRSS14, 
the survival rate was significantly poor (Fig. 30). PRSS14high and 
FOShigh group in ER negative patients showed the lowest survival 
among all the groups. Therefore, it is proposed that at least FOS, 
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EFEMP2, and MMP13 along with PRSS14 and SPPL2B can be 
valuable prognosis markers and therapeutic targets of ER negative 
breast cancer, especially triple negative breast cancer. 
 
 
 Prss14 contributes in metastasis by providing signals from 
both inside and outside of the cell 
It is well documented that Prss14 promotes cancer progression 
and metastasis through its protease activity against diverse 
substrates involved in cancer (List, 2009; Uhland, 2006). Prss14 
enhances cancer cell invasion, angiogenesis, and metastasis by 
remodeling extracellular matrix (ECM) through cleavage of ECM 
molecules as well as activation of uPA and MMP3 (Jin et al., 2006; 
Lee et al., 2000; Tripathi et al., 2011). Prss14 also activates growth 
factor and receptors and induces signaling pathways associated with 
cancer formation and progression, such as PAR2-NFκB, HGF-c-
Met, and Tie2 downstream signaling pathway (Kim et al., 2011; List 
et al., 2005; Sales et al., 2015; Szabo et al., 2011; Zoratti et al., 2016). 
So far many studies has focused on protease activity of Prss14. 
This study presents a novel mechanism that PICD of Prss14 
produced by RIP process serves to induce tumor progression and 
metastasis through transcriptional modulation. The mature Prss14 is 
shed by TACE upon various stimuli. Active Prss14 promotes ECM 
degradation and activates its substrates that are associated with 
cancer progression. Meanwhile, membrane-anchored N-terminal 
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fragment is further processed by SPPL2b resulting in PICD 
generation. The PICD translocates to the nucleus and regulates 
transcription of target genes including transcription factors, 
cytokines, and genes involved in ubiquitin proteasome pathway. 
These target genes promote metastasis through induction of EMT 
and modulation of tumor microenvironment for favorable metastasis. 
Therefore, Prss14 can function dually in cancer progression and 
metastasis through both extracellular protease activity and 
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막단백질분해효소인 Prss14은 다양한 상피세포암에 과발현되어 있으며, 
그것이 암의 발생과, 진행, 전이에 매우 중요한 역할을 한다는 것이 
보고되어있다. Prss14은 serum, TGF-, PMA 등 다양한 자극에 
의해서 ectodomain shedding이 일어나는데, 그 이후 membrane에 
남겨진 N-말단단편에 대해서는 알려진 바가 없다. 본 연구에서는 
Prss14이 shedding된 이후, regulated intramembrane proteolysis에 
의해 잘려서 intracellular domain (PICD)이 만들어진다는 것을 밝혔다. 
PMA를 처리하면 TACE에 의해 Prss14의 ectodomain shedding이 
일어나고 SPPL2b는 membrane에 남아있는 N-terminal fragment를 
자른다. 이렇게 만들어진 PICD는 membrane에서 떨어져나와, 핵으로 
이동하여 전사조절에 관여한다. RNA-sequencing에 의한 전사체분석을 
통하여 PICD의 타겟유전자가 전사인자, 사이토카인, 세포의 이동과 
침습에 관여하는 유전자, ubiquitin proteasome pathway에 관련된 
유전자들을 포함하고 있다는 것을 밝혔다. 이들 유전자는 Fos, Tnf, Ubc 
유전자들을 중심으로 기능적인 network를 이루고 있다. 또한, PICD 
타겟 유전자들이 세포의 이동, 침습, epithelial-mesenchymal 
transition (EMT), 암 미세환경 조절을 포함한 암과 관련된 기작에 
관여하고 있다는 것을 확인하였다. PICD를 발현시킨 세포에서는 
EMT에서 보이는 세포의 모양이 변화가 관찰되었고, pre-EMT 
marker인 E-cadherin의 발현이 감소하고 post-EMT marker인 
Viment의 발현이 증가하였다. 더나아가, PICD를 발현하는 세포에서는 
세포의 이동과 침습성이 증가하는 것을 관찰하였다. 세포의 이동과 
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침습은 SPPL2b를 knockdown하여 PICD가 적게 만들어지는 
세포에서는 감소해 있었으며, control 세포에서 관찰되는 PMA에 의한 
세포 이동과 침습이 SPPL2b-KD 세포에서는 관찰되지 않았다. 또한 
PMA를 처리하지 않아도 SPPL2b-KD 세포에 PICD만 발현시켜도 
세포의 이동과 침습이 증가하는 것을 통해 세포의 이동과 침습이 
PICD에 의존적으로 조절됨을 확인하였다. Prss14이 과발현되어 있으며, 
과발현정도가 암의 진행과 암환자의 생존율에 관련이 있다고 알려져있는 
유방암 환자에서 PICD가 만들어지는 현상의 clinical relevance를 
확인하였다. 유방암 환자에서 Prss14이 높을 때 PICD 타겟 유전자들의 
발현이 통계적으로 유의하게 높았다. 또한, TCGA 유방암 환자의 
데이터를 이용한 생존율 분석을 통해서 SPPL2b와 PICD의 
타겟유전자들이 Prss14과 함께 높게 발현될 때 ER-negative 유방암 
환자에서 생존율이 크게 감소하는 것을 확인하였다. 따라서 Prss14 
뿐만 아니라, SPPL2b와 PICD 타겟유전자들은 ER-negative 유방암 
환자의 유용한 진단 마커로 쓰일 수 있으며 치료 타켓이 될 수 있음을 
알 수 있다. 본 연구는 막단백질분해효소인 Prss14이 타겟유전자들의 
전사에 관여하여 암 전이를 조절하는 새로운 기능을 밝혔고, 이 
조절기작이 암 환자에게서도 중요함을 제시하였다. 
 
 
